Conference Reports for NATAP

Back

18th European AIDS Conference October 27th-30th, 2021 Online & United Kingdom     SOLAR 3D: A PROSPECTIVE STUDY SWITCHING TO DTG/3TC FROM 3- OR 4-DRUG ART FOR MAINTENANCE OF VIRAL SUPPRESSION WITH HISTORIC M184V/I MUTATION AND PRIOR VIROLOGICAL FAILURES: 48 WEEK PRIMARY ENDPOINT RESULTS - (03/21/21)   Distinct groupings of people with HIV and pain associate differently with pain-related healthcare use and health-related quality-of-life (HRQoL): findings from the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study - (12/03/21)   Efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing nrti resistances: real world data - (11/10/21)   Integrase inhibitor drug resistance in clinical practice in the United Kingdom - (11/10/21)   Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study - (11/06/21)   People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV-2 infection SARS-CoV-2 Risk No Higher With Well-Controlled HIV Than in HIV-Negatives - Mark Mascolini (11/06/21)   Tolerability and antiviral activity of bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study - (11/06/21)   Gender-related differences in safety after switching to BICTEGRAVIR/TAF/FTC in "real life" - (11/06/21)   Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study) - (11/06/21)   Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study - (11/06/21)   More than half of well-treated persons living with HIV have angiography verified coronary artery disease Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/06/21)   Increased neurocognitive impairment and white matter damaged in young adults with perinatal HIV infection. A case-control study - Mark Mascolini (11/06/21)   EACS: Long-Acting Injectable Cabotegravir + Rilpivirine. - (11/06/21)   A fog that impacts everything: understanding quality of life in people living with HIV and cognitive impairment - poor mental & physical function - (11/06/21)   Long-term HIV survivors and adults 65 or over with HIV: two separate profiles with different needs - (11/03/21)   Comorbidities in women living with HIV: a systematic review - higher rates for kidney, bone, heart, neurocognitive diseases - (11/03/21)   Themes of Aging from Older PLWH: A fog that impacts everything: understanding quality of life in people living with HIV and cognitive impairment - (11/03/21)   Comparison of baseline characteristics and cardiovascular outcomes of a multicentre UK cohort of people living with HIV with previously reported cohorts - (11/03/21)   Correlation between inflammatory biomarkers with four cardiovascular disease (CVD) risk models in aging patients living with HIV - (11/03/21)   Incidence of diabetes mellitus in PLWHIV: impact of antiretroviral therapy - (11/03/21)   Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors - (11/03/21)   Liver disease in people living with HIV (PLWHIV) after the microelimination of HCV infection: non-viral hepatitis & NAFLD - (11/02/21)   Factors associated with excess depressive disorders in women and men living with HIV in south-western France compared to the general French population - see slides below - (11/02/21)   Faster lung function decline in well-treated people living with HIV compared with uninfected controls: a longitudinal matched cohort study - Mark Mascolini (11/02/21)   Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study (SHCS) - (11/02/21)   Stigma Drives Higher Depression Rate in HIV+ Men and Women in France - Mark Mascolini (11/02/21)   Bacterial Pneumonia Incidence Drops Sharply in Swiss HIV Cohort Study - Mark Mascolini (11/02/21)   Incidence and risk factors for suicide, violent/accidental deaths, and substance abuse deaths in persons living with HIV - (11/02/21)   Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA - (11/02/21)   Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/02/21)   Hepatitis C elimination in time of COVID-19 pandemic: the experience of University Hospital Center in Paris, France - (11/01/21)   Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/01/21)   Hepatic steatosis associated with integrase strand transfer inhibitors - does the substance matter? - (11/01/21)   Insulin resistance in PWH is associated with abdominal obesity and prior exposure to thymidine analogues and/or didanosine - (11/01/21)   Safety Profile of Cabotegravir + Rilpivirine During Oral Lead-In and Through Long-Acting Therapy: Pooled Analysis of the Phase 3 FLAIR, ATLAS, and ATLAS-2M Studies - (11/01/21)   UNDERSTANDING THE PERCEIVED THERAPEUTIC NEED AND VALUE ASSOCIATED WITH NOVEL LONG-ACTING ANTIRETROVIRAL REGIMENS AMONG PEOPLE LIVING WITH HIV IN 12 EUROPEAN COUNTRIES - (11/01/21)   European Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes - (11/01/21)   Highly Effective Two-drug Regimens of an Integrase Inhibitor and Reverse Transcriptase Inhibitor in Real-World Setting - Data from COMBINE-2 Study - (11/01/21)   12-month outcomes - patient satisfaction - of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated PLHIV in Germany: Real-world data from the German URBAN cohort - (11/01/21)   Evaluating the relationship between inflammation biomarker interleukin-6 (IL-6) levels and residual, low-Level viraemia in HIV-1 suppressed participants in the TANGO study at week 96 (WK96) - (11/01/21)   The potential clinical impact of the observed differences in IL-6, a marker of inflammation, associated with some antiretroviral regimens - (11/01/21)   Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/01/21)   PLW Presented Late To Care in WHO European Region 2019 - (11/01/21)   Viral Suppression in 40 Countries in Europe & Central Asia 2020 - (11/01/21)   Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/01/21)   SWITCHING TO DTG/3TC IS NON-INFERIOR TO CONTINUING CURRENT ANTIRETROVIRAL REGIMEN AT WEEK 48: SALSA SUBGROUP ANALYSES - (10/31/21)   SWITCHING TO DTG/3TC IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN AT WEEK 144: TANGO SUBGROUP ANALYSES - (10/31/21)   2 year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: Real-world data from the German JUNGLE cohort - (10/31/21)   Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): Examining Healthcare Staff Attitudes During a Hybrid III Implementation-Effectiveness Trial Implementing Cabotegravir + Rilpivirine Long-Acting Injectable (CAB + RPV LA) for People Living With HIV - (10/30/21)   Perspectives on the Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators From Patients Receiving Cabotegravir + Rilpivirine Long-Acting Injectable Treatment (CAB + RPV LA): Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) - (10/30/21)   Healthcare Staff Perspectives on the Implementation of HIV Injectable Treatment: Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) - (10/30/21)   Characteristics, treatment patterns, and viral load for treatment-experienced people living with HIV and switching to an MTR or STR ARV after 2018 - (10/30/21)   Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips - (10/30/21)   Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide - (10/30/21)   Evaluating virological outcomes in people with HIV on stable ART with reduced frequency of HIV viral load monitoring during the COVID-19 pandemic Less Viral Load Tracking During COVID Has No Immediate Ill Effects - Mark Mascolini (10/30/21)   Domestic abuse (DA) screening in people living with HIV (PLWH) More Domestic Abuse Screening in HIV+ During COVID Discloses Spike in Reports - Mark Mascolini (10/30/21)   Immunogenicity of mRNA vaccination against SARS-CoV-2 in persons living with HIV (PLWHs) with low CD4 count or previous AIDS Immune Response to mRNA COVID Vaccines Weaker in HIV+ With Low CD4s - Mark Mascolini (10/30/21)   Chemsex practice in men who have sex with men: reduction or relapse during lockdown? Results of the CheRRLock study COVID Lockdown Boosts Chemsex Use, Cuts Sex Partners in Paris MSM - Mark Mascolini (10/30/21)   New HCV Diagnoses Down by Two Thirds in HIV+ Swiss MSM 2010-2020 - Mark Mascolini (10/30/21)   Chemsex practice in men who have sex with men: reduction or relapse during lockdown? Results of the CheRRLock study COVID Lockdown Boosts Chemsex Use, Cuts Sex Partners in Paris MSM - Mark Mascolini (10/29/21)   Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting - (10/29/21)   Progression to Anal Cancer Precursor 11 Per 100 Person-Years in HIV+ MSM - Mark Mascolini (10/29/21)   Renal Safety of On-demand and Daily TDF-FTC for HIV Pre-exposure Prophylaxis in the ANRS-PREVENIR Study - (10/29/21)   Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 12-month effectiveness, persistence, and safety in a multi-country cohort study - (10/29/21)   Patient-reported outcome (PRO) measures at 12 months in a real-world cohort of people living with HIV with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel - (10/29/21)   COMPARATIVE EFFICACY OF FOSTEMSAVIR VERSUS IBALIZUMAB IN HEAVILY TREATMENT-EXPERIENCED HIV PATIENTS - (10/29/21)   LONG-TERM INFLAMMATION BIOMARKER CHANGES WITH FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY - (10/29/21)   IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED WEEK 144 ANALYSIS OF THE GEMINI-1 AND GEMINI-2 CLINICAL STUDIES - (10/29/21)   Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV (CAPELLA study) - (10/29/21)   EMERGENT RESISTANCE TO ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR: WEEK 96 RESULTS OF THE PHASE 3 BRIGHTE STUDY IN HEAVILY TREATMENT-EXPERIENCED ADULTS LIVING WITH MULTIDRUG-RESISTANT HIV-1 - (10/29/21)   Recent Abacavir Use and Incident Cardiovascular Disease in Contemporary Treated PLWH within the RESPOND Cohort Consortium - (10/29/21)   Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials - (10/29/21)   Outcomes for Participants During Long-Term Follow-Up After Discontinuation of Cabotegravir + Rilpivirine Long-Acting in the Phase 3/3b Clinical Trials - (10/29/21)   Efficacy and Safety of Islatravir in Combination With Doravirine Through 144 Weeks for Treatment-Naïve Adults With HIV-1 Infection in a Phase 2b Trial - (10/29/21)   Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 26 weeks of treatment - (10/28/21)   Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV (PLWH) within the RESPOND cohort consortium - Mark Mascolini - (10/28/21)   Multiclass Resistance to Antiretrovirals Waning in Europe - Mark Mascolini - (10/28/21)   High HIV Positivity Rate When Self-Tests Distributed by LGBT Health Center Clients - Mark Mascolini - (10/28/21)   Kidney Toxicity Rare With Daily or On-Demand (As-Needed) PrEP - Mark Mascolini - (10/28/21)   Safety and Efficacy of Doravirine in Treatment-Naïve Adults with HIV-1: 4 Years of Experience From the DRIVE-FORWARD and DRVIVE-AHEAD Clinical Trials - (10/28/21)   ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings - (10/28/21)   ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV - (10/28/21)   Evaluating the relationship between inflammation biomarker interleukin-6 (IL-6) levels and residual, low-Level viraemia in HIV-1 suppressed participants in the TANGO study at week 96 (WK96) - (10/27/21)   Durable efficacy and safety of DTG + 3TC in treatment-naive people with HIV-1 stratified by age: 144-week results from GEMINI-1 and -2 - (10/27/21)   Incidence of hypertension in people living with HIV receiving InSTI versus other third-drug ART regimens in the RESPOND cohort - (10/27/21)   High incidence of subclinical peripheral artery disease in people living with HIV in Denmark: a 2-year follow-up study - (10/27/21)   Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF - (10/27/21)   Week 192 bone and renal markers from the ADVANCE trial - (10/27/21)   ViiV Healthcare presents real-world evidence at EACS 2021 reinforcing the use of its 2-drug regimens Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) for the treatment of people living with HIV - (10/27/21)   Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors - (10/27/21)   GENDER DIFFERENCES OF SUBCLINICAL ATHEROSCLEROSIS BURDEN IN CAROTID AND FEMORAL TERRITORIES IN PEOPLE LIVING WITH HIV: A SUBANALYSIS OF THE VASI STUDY - (10/27/21)   Comorbidities and antiretroviral utilization among people living with HIV in the United States - (10/27/21)   Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA - (10/27/21)   Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021 - (10/27/21)   Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection - (10/25/21)